Skip to main content
Top

01-01-2015 | Ophthalmologic cancers | Article

8. Management of High-Risk Retinoblastoma

Authors: Guillermo L. Chantada, M.D., Ph.D., María T. G. de Dávila, M.D., Ph.D.

Publisher: Springer International Publishing

Abstract

Invasion to the choroid, the sclera, and the optic nerve all constitute risk factors for extraocular relapse detected in enucleated eyes with retinoblastoma. Specifically, different degrees of invasion to these structures are associated with different risk and adjuvant therapy is tailored according to their presence. The relapse risk of children with isolated choroidal invasion is lower than 6 %, even in the higher risk subgroups with massive invasion and up to two thirds of those who relapse may be retrieved with intensive therapy. Hence, some groups use adjuvant therapy to further reduce the rate of extraocular relapse, while others do not give any treatment after enucleation. Most groups use adjuvant chemotherapy for children with postlaminar optic nerve invasion, but those with minor degrees of invasion may not need it. Since the relapse rate of these patients is low, the decision to use adjuvant therapy should be balanced in each setting with the possibility of fatal toxicities associated to chemotherapy.
Most groups use adjuvant therapy for those with scleral invasion and those with tumor at the resection margin of the optic nerve and more intensive regimens or orbital radiotherapy are recommended. Relapse in the central nervous system is the most common site for extraocular relapse in children receiving adjuvant therapy and it may become a sanctuary site when lower doses or drugs with low penetration to the cerebrospinal fluid are used. Molecular studies to determine the kinetics of minimal disease dissemination may provide more information.
Literature
Abramson DH. Retinoblastoma: saving life with vision. Annu Rev Med. 2014;65:171–84. doi:10.1146/annurev-med-061312-123455.CrossRefPubMed
Aerts I, Sastre-Garau X, Savignoni A, Lumbroso-Le Rouic L, Thebaud-Leculee E, Frappaz D, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31(11):1458–63. doi:10.​1200/​JCO.​2012.​42.​3962.CrossRefPubMed
Antoneli CB, Steinhorst F, de Cassia Braga Ribeiro K, Novaes PE, Chojniak MM, Arias V, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98(6):1292–8. doi:10.​1002/​cncr.​11647.CrossRefPubMed
Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, Soares FA, Arias VA, Novaes PE, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29(10):700–4. doi:10.​1097/​MPH.​0b013e31814fb7ea​.CrossRefPubMed
Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009;100(10):1627–37. doi:10.​1038/​sj.​bjc.​6605029.CrossRefPubMedCentralPubMed
Bellaton E, Bertozzi AI, Behar C, Chastagner P, Brisse H, Sainte-Rose C, et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol. 2003;87(3):327–9.CrossRefPubMedCentralPubMed
Biojone E, Queiroz Rde P, Valera ET, Odashima NS, Takayanagui OM, Viana MB, et al. Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(1):89–95. doi:10.​3109/​10428194.​2011.​606939.CrossRefPubMed
Bosaleh A, Sampor C, Solernou V, Fandino A, Dominguez J, de Davila MT, et al. Outcome of children with retinoblastoma and isolated choroidal invasion. Arch Ophthalmol. 2012;130(6):724–9. doi:10.​1001/​archophthalmol.​2012.​567.CrossRefPubMed
Chantada G, Fandino A, Davila MT, Manzitti J, Raslawski E, Casak S, et al. Results of a prospective study for the treatment of retinoblastoma. Cancer. 2004a;100(4):834–42. doi:10.​1002/​cncr.​11952.CrossRefPubMed
Chantada GL, Dunkel IJ, de Davila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004b;88(8):1069–73. doi:10.​1136/​bjo.​2003.​037044.CrossRefPubMedCentralPubMed
Chantada GL, Casco F, Fandino AC, Galli S, Manzitti J, Scopinaro M, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology. 2007a;114(11):2083–9. doi:10.​1016/​j.​ophtha.​2007.​01.​012.CrossRefPubMed
Chantada GL, Dunkel IJ, Antoneli CB, de Davila MT, Arias V, Beaverson K, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer. 2007b;49(3):256–60. doi:10.​1002/​pbc.​21067.CrossRefPubMed
Chantada GL, Gonzalez A, Fandino A, de Davila MT, Demirdjian G, Scopinaro M, et al. Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma. J Pediatr Hematol Oncol. 2009a;31(5):325–9. doi:10.​1097/​MPH.​0b013e3181923cc5​.CrossRefPubMed
Chantada GL, Guitter MR, Fandino AC, Raslawski EC, de Davila MT, Vaiani E, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009b;52(2):218–22. doi:10.​1002/​pbc.​21735.CrossRefPubMed
Chantada GL, Fandino AC, Guitter MR, Raslawski EC, Dominguez JL, Manzitti J, et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer. 2010;55(1):60–6. doi:10.​1002/​pbc.​22503.PubMed
Chantada G, Luna-Fineman S, Sitorus RS, Kruger M, Israels T, Leal-Leal C, et al. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer. 2013a;60(5):719–27. doi:10.​1002/​pbc.​24468.CrossRefPubMed
Chantada GL, Sampor C, Bosaleh A, Solernou V, Fandino A, de Davila MT. Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol. 2013b;131(9):1127–34. doi:10.​1001/​jamaophthalmol.​2013.​260.CrossRefPubMed
Chantada GL, Fandino AC, Schvartzman E, Raslawski E, Schaiquevich P, Manzitti J. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatr Blood Cancer. 2014;61(5):821–6. doi:10.​1002/​pbc.​24857.CrossRefPubMed
Cuenca A, Giron F, Castro D, Fandino A, Guitter M, de Davila MT, et al. Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol. 2009;127(8):1006–10. doi:10.​1001/​archophthalmol.​2009.​174.CrossRefPubMed
de Graaf P, Goricke S, Rodjan F, Galluzzi P, Maeder P, Castelijns JA, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012;42(1):2–14. doi:10.​1007/​s00247-011-2201-5.CrossRefPubMedCentralPubMed
Dimaras H, Rushlow D, Halliday W, Doyle JJ, Babyn P, Abella EM, et al. Using RB1 mutations to assess minimal residual disease in metastatic retinoblastoma. Transl Res. 2010;156(2):91–7. doi:10.​1016/​j.​trsl.​2010.​05.​009.CrossRefPubMed
Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, et al. Retinoblastoma. Lancet. 2012;379(9824):1436–46. doi:10.​1016/​S0140-6736(11)61137-9.CrossRefPubMed
Eagle Jr RC. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203–9. doi:10.​1043/​1543-2165-133.​8.​1203.PubMed
Edry Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, Bauerle T, et al. Lung-residing metastatic and dormant neuroblastoma cells. Am J Pathol. 2011;179(1):524–36. doi:10.​1016/​j.​ajpath.​2011.​03.​020.CrossRefPubMedCentralPubMed
Friedman DN, Sklar CA, Oeffinger KC, Kernan NA, Khakoo Y, Marr BP, et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer. 2013;60(4):694–9. doi:10.​1002/​pbc.​24280.CrossRefPubMed
Kaliki S, Shields CL, Shah SU, Eagle Jr RC, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129(11):1422–7. doi:10.​1001/​archophthalmol.​2011.​289.CrossRefPubMed
Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin JP, Shields JA, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013;120(5):997–1003. doi:10.​1016/​j.​ophtha.​2012.​10.​044.CrossRefPubMed
Kashyap S, Meel R, Pushker N, Sen S, Bakhshi S, Sreenivas V, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer. 2012a;58(3):356–61. doi:10.​1002/​pbc.​23239.CrossRefPubMed
Kashyap S, Sethi S, Meel R, Pushker N, Sen S, Bajaj MS, et al. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country. Arch Pathol Lab Med. 2012b;136(2):190–3. doi:10.​5858/​arpa.​2010-0759-OA.CrossRefPubMed
Killer HE, Flammer J, Miller NR. Glaucoma and cerebrospinal fluid pressure. Ophthalmology. 2008;115(12):2316–7. doi:10.​1016/​j.​ophtha.​2008.​06.​037. author reply 7.CrossRefPubMed
Laurent VE, Sampor C, Solernou V, Rossi J, Gabri M, Eandi-Eberle S, et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer. 2013;49(13):2892–9. doi:10.​1016/​j.​ejca.​2013.​04.​021.CrossRefPubMed
Levin MH, Gombos DS, O’Brien JM. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol. 2011;129(11):1487–9. doi:10.​1001/​archophthalmol.​2011.​304.CrossRefPubMed
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41–53, viii. doi:10.1016/j.ohc.2004.11.003.
Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96(2):217–22.CrossRefPubMed
Potter SL, Berg S, Ingle AM, Krailo M, Adamson PC, Blaney SM. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children’s Oncology Group trial (P9962). Pediatr Blood Cancer. 2012;58(3):362–5. doi:10.​1002/​pbc.​23317.CrossRefPubMedCentralPubMed
Radhakrishnan V, Sharma S, Vishnubhatla S, Bakhshi S. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Br J Ophthalmol. 2013;97(1):52–8. doi:10.​1136/​bjophthalmol-2012-301977.CrossRefPubMed
Rubin CM, Robison LL, Cameron JD, Woods WG, Nesbit Jr ME, Krivit W, et al. Intraocular retinoblastoma group V: an analysis of prognostic factors. J Clin Oncol. 1985;3(5):680–5.PubMed
Sastre X, Chantada GL, Doz F, Wilson MW, de Davila MT, Rodriguez-Galindo C, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199–202. doi:10.​1043/​1543-2165-133.​8.​1199.PubMed
Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77(9):544–8.CrossRefPubMedCentralPubMed
Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73(3):692–8.CrossRefPubMed
Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–80. doi:10.​1016/​j.​ophtha.​2006.​06.​018.CrossRefPubMed
Stannard C, Lipper S, Sealy R, Sevel D. Retinoblastoma: correlation of invasion of the optic nerve and choroid with prognosis and metastases. Br J Ophthalmol. 1979;63(8):560–70.CrossRefPubMedCentralPubMed
Stannard C, Sealy R, Hering E, Hough J, Knowles R, Lecuona K, et al. Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54(5):1446–54.CrossRefPubMed
Sullivan EM, Wilson MW, Billups CA, Wu J, Merchant TE, Brennan RC, et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014;36(6):e335–40. doi:10.​1097/​MPH.​0000000000000141​.CrossRefPubMedCentralPubMed
Torbidoni AV, Laurent VE, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Rossi J, de Dávila MT, Alonso C, Alonso DF, Chantada GL. Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. JAMA Ophthalmol. 2015 2015. doi: 10.​1001/​jamaophthalmol.​2015.​0900 [Epub ahead of print].
Wilson MW, Qaddoumi I, Billups C, Haik BG, Rodriguez-Galindo C. clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br J Ophthalmol. 2011;95(4):553–8. doi:10.​1136/​bjo.​2009.​177444.CrossRefPubMed